2022
Advances in Multimodality Imaging in Cardio-Oncology JACC State-of-the-Art Review
Baldassarre LA, Ganatra S, Lopez-Mattei J, Yang EH, Zaha VG, Wong TC, Ayoub C, DeCara JM, Dent S, Deswal A, Ghosh AK, Henry M, Khemka A, Leja M, Rudski L, Villarraga HR, Liu JE, Barac A, Scherrer-Crosbie M, Councils A. Advances in Multimodality Imaging in Cardio-Oncology JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2022, 80: 1560-1578. PMID: 36229093, DOI: 10.1016/j.jacc.2022.08.743.Peer-Reviewed Original ResearchConceptsCardio-oncology patientsAdverse cardiovascular effectsLong-term survivorsPopulation of patientsCardiovascular complicationsPregnant patientsCardiovascular effectsCardiac massAntineoplastic therapyJACC StateVascular toxicityPatientsMultimodality imagingCancerImagingNumerous advancesReviewComplicationsAtherosclerosisTherapyPopulationDiseaseSurvivorsDiagnosisNovel Cardiac Computed Tomography Methods for the Assessment of Anthracycline Induced Cardiotoxicity
Feher A, Baldassarre LA, Sinusas AJ. Novel Cardiac Computed Tomography Methods for the Assessment of Anthracycline Induced Cardiotoxicity. Frontiers In Cardiovascular Medicine 2022, 9: 875150. PMID: 35571206, PMCID: PMC9094702, DOI: 10.3389/fcvm.2022.875150.Peer-Reviewed Original ResearchCardiac structureEpicardial coronary arteriesAnthracycline-induced cardiotoxicityAnti-cancer therapyCoronary vasoreactivityCoronary anatomyCoronary arteryInduced cardiotoxicityCardiac functionCardiotoxic effectsPreprocedural planningExtracellular volumeMyocardial deformationPotential roleCardiotoxicityMolecular imagingCurrent manuscriptVasoreactivityComputed tomography methodArteryAnthracyclinesTherapyCardiacPlaquesEvaluation
2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting systemAdverse cardiovascular events in patients treated with mogamulizumab
Kwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. PMID: 38559371, PMCID: PMC10978139, DOI: 10.1016/j.ahjo.2021.100049.Peer-Reviewed Original ResearchAdverse cardiovascular eventsMogamulizumab therapyCardiovascular eventsHeart failureAdverse outcomesNon-cardiovascular eventsWorld Health Organization databaseFatal adverse outcomesT-cell leukemiaACE occurrenceMogamulizumab treatmentNew hypertensionAdverse eventsCardiac deathVentricular arrhythmiasFatal outcomeUnique patientsCardiovascular toxicityMyocardial infarctionImportant treatmentHigh mortalityPatientsMogamulizumabTherapyOrganization databaseCardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization
O’Quinn R, Ferrari VA, Daly R, Hundley G, Baldassarre LA, Han Y, Barac A, Arnold A. Cardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization. JACC CardioOncology 2021, 3: 191-200. PMID: 34396324, PMCID: PMC8352183, DOI: 10.1016/j.jaccao.2021.04.011.Peer-Reviewed Original ResearchMogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma
Kwan JM, Odanovic N, Arbune A, Higgins A, Henry M, Greif D, Foss F, Baldassarre LA. Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma. JACC Case Reports 2021, 3: 1018-1023. PMID: 34317676, PMCID: PMC8311348, DOI: 10.1016/j.jaccas.2021.04.001.Peer-Reviewed Original Research
2019
The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics
Soufer A, Baldassarre LA. The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics. Current Treatment Options In Cardiovascular Medicine 2019, 21: 28. PMID: 31104180, DOI: 10.1007/s11936-019-0732-5.Peer-Reviewed Original ResearchCardiac magnetic resonanceCardiac toxicityCardiac magnetic resonance imagingNon-invasive workupImmune checkpoint inhibitorsSubclinical LV dysfunctionMyocardial tissue characteristicsCancer therapyPurpose of ReviewTheMagnetic resonance imagingCheckpoint inhibitorsLA fibrosisLV dysfunctionMicrocirculatory dysfunctionNon-invasive methodMagnetic resonanceCardiac structureResonance imagingMyocardial strainTissue characteristicsDysfunctionCancer therapeuticsTherapyToxicityFurther researchNuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods
Soufer A, Liu C, Henry ML, Baldassarre LA. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. Journal Of Nuclear Cardiology 2019, 27: 1210-1224. PMID: 30868378, DOI: 10.1007/s12350-019-01671-6.Peer-Reviewed Original ResearchConceptsCardiac toxicityPre-clinical cardiotoxicityCardiac magnetic resonanceNuclear cardiologyCardiovascular outcomesNon-invasive imagingCardiovascular toxicityChemotherapeutic agentsCancer treatmentEarly detectionCardiac imagingCancer therapyCancer therapeuticsCardiologyToxicityMagnetic resonanceTreatmentImagingEchocardiographyPatientsCardiotoxicityTherapyCancerSeverityCare